1
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Phase 2/3
1
Status
Withdrawn
1
Terminated
1
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Head & Neck
2
Endocrine
2
Conditions
Thyroid Neoplasms
2
Thyroid Carcinoma, Anaplastic
2
Head and Neck Neoplasms
1
Interventions
Cisplatin
3202
Cyclophosphamide
3195
Carboplatin
2977
Radiotherapy
2790
Paclitaxel
2718
Gemcitabine
2572
pembrolizumab
2385
Bevacizumab
2209
Docetaxel
2199
Fluorouracil
1851
Capecitabine
1833
Oxaliplatin
1742
Dexamethasone
1605
Nivolumab
1581
Doxorubicin
1501
Rituximab
1488
Magnetic Resonance Spectroscopy
1387
Etoposide
1346
Irinotecan
1248
Leucovorin
1226
Drug Therapy
1205
Cytarabine
1130
Pemetrexed
1076
fludarabine
1063
Specimen Handling
1017
Vincristine
964
Cetuximab
945
Trastuzumab
945
Prednisone
942
Lenalidomide
937
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
combretastatin
×
Clear all
NCT00507429
2014-06-09
FACT
Mateon Therapeutics
Phase 2/3
Terminated
80 enrolled
10 charts
NCT01701349
2014-05-01
FACT2
Mateon Therapeutics
Phase 3
Withdrawn